You are here

Merck KGaA

Germany's Merck breaks ground on $321m biomanufacturing center

BioProcess International

Thu, 04/25/24 - 05:57 pm

drug manufacturing

Merck KGaA signs $1.4B biobuck deal with Caris to expand ADC pipeline

Fierce Biotech

Thu, 04/4/24 - 11:17 am

antibody-drug conjugates

Caris Life Sciences

Merck KGaA's MilliporeSigma drops €300M on Korean biologics plant with plans to create 300 new jobs

Fierce Pharma

Thu, 03/21/24 - 06:39 pm

drug manufacturing

Despite pharma growth, Merck KGaA's CDMO slowdown plays into company's overall sales decline

Fierce Pharma

Sun, 03/10/24 - 08:40 pm

Merck KGaA bets on Inspirna’s colorectal cancer drug ompenaclid

Pharmaphorum

Thu, 01/4/24 - 10:09 am

colorectal cancer

Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies

BioSpace

Wed, 12/6/23 - 10:44 am

clinical trials

relapsing multiple sclerosis

Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront

Fierce Biotech

Tue, 12/5/23 - 11:07 am

Abbisko Therapeutics

Merck KGaA's pharma unit joins the healthcare migration to Boston's Seaport innovation hub

Fierce Pharma

Tue, 11/14/23 - 09:59 pm

Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead

Fierce Biotech

Mon, 10/30/23 - 11:58 am

PARP inhibitors

Gilead Sciences

Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data

Fierce Biotech

Wed, 10/11/23 - 10:20 am

multiple sclerosis

clinical trials

Merck KGaA doubles up on AI partners, tapping BenevolentAI and Exscientia for drug discovery push

Fierce Biotech

Wed, 09/20/23 - 08:37 am

artificial intelligence

Merck KGaA invests €23 million to expand cell culture media production

Biopharma Reporter

Mon, 07/17/23 - 08:47 am

The waxing and waning of the speedy approval

EP Vantage

Mon, 05/15/23 - 09:58 am

accelerated approvals

Bristol Myers Squibb

Industry Seeks to Stimulate Innovation Through Grant Programs

BioSpace

Wed, 05/3/23 - 11:38 am

Thermo Fisher Scientific

Finding the big spenders beyond big pharma

EP Vantage

Mon, 04/24/23 - 10:15 am

Gilead Sciences

Moderna Therapeutics

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Big pharma holds steady on research spending

EP Vantage

Fri, 04/21/23 - 10:03 am

Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links

Fierce Biotech

Wed, 04/12/23 - 11:52 am

multiple sclerosis

Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends

Endpoints

Mon, 03/27/23 - 10:04 pm

Pages